Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR Center in Barcelona

The center will collect real-world data on AMBAR clinical program

- AMBAR Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-profit medical foundation Ace Alzheimer Center Barcelona in diagnosing and treating Alzheimer's patients, including application of AMBAR (Alzheimer Management by Albumin Replacement)

- The AMBAR clinical program, based on periodic plasma exchange with albumin, has shown a delay in the cognitive and functional progression of Alzheimer's disease in mild-to-moderate patients

- Ace Alzheimer Center will manage the center, to be located on its premises in Barcelona. Grifols will partner with other leading medical institutions to open expected future centers in the EU, U.S. and China, obtaining AMBAR data from clinical practice and advancing further in the therapeutic management of the disease

BARCELONA, Spain, May 19, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR Center, where AMBAR procedure for Alzheimer's disease will be applied to obtain data from clinical practice.

This next phase in the fight against Alzheimer's will serve to optimize the application of AMBAR in medical practice and make it a new option for suitable patients as soon as possible. It comes after more than 15 years of advancing Alzheimer's research through the AMBAR clinical program, which includes an international clinical study demonstrating that periodic plasma exchange with albumin safely slows the cognitive and functional progression of Alzheimer's in mild-to-moderate patients.

The overall patient experience at AMBAR Center will combine the know-how that Grifols has accumulated as developer of AMBAR with Ace Alzheimer Center's expertise in diagnosing and treating Alzheimer's patients, as well as in basic and applied research. Its knowledge also includes applying AMBAR through its participation in the development of the clinical program since it began in 2004.

AMBAR Center will be located at Ace's facilities in Barcelona and managed by its healthcare professionals including neurologists, neuropsychologists, apheresis specialists and nurses trained and experienced in AMBAR.